Literature DB >> 3021994

Abelson murine leukemia virus variants with increased oncogenic potential.

K Murtagh, G Skladany, J Hoag, N Rosenberg.   

Abstract

A number of strains of Abelson murine leukemia virus (A-MuLV) with various abilities to transform cells have been identified. Among these is the A-MuLV-P90 strain, a mutant derived from A-MuLV-P120 that encodes an A-MuLV protein missing sequences that are normally present at the extreme carboxy terminus of P120 (N. Rosenberg and O. N. Witte, J. Virol. 33:340-348, 1980). This virus transforms NIH 3T3 cells efficiently but does not transform a high frequency of lymphoid cells in vitro or in vivo. In this communication, we show that of the relatively few tumors induced by A-MuLV-P90 nearly all contained new variant viruses that stably expressed either larger or smaller A-MuLV proteins. Strains that expressed larger A-MuLV proteins behaved like A-MuLV-P120 in transformation assays, whereas those expressing smaller A-MuLV proteins induced a high frequency of tumors after a short latent period in vivo but failed to transform large numbers of lymphoid cells in vitro. Thus, these latter viruses separated the requirements for in vitro transformation of lymphoid cells from those for tumor induction. All of the variants differed from A-MuLV-P90 in the carboxy-terminal region of the A-MuLV protein, suggesting that sequences in this region play a key role in the ability of the virus to interact with hematopoietic cells in vivo and in vitro.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3021994      PMCID: PMC288931     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  Structure of the murine leukemia virus envelope glycoprotein precursor.

Authors:  O N Witte; D F Wirth
Journal:  J Virol       Date:  1979-02       Impact factor: 5.103

2.  Phosphorylation of the Abelson murine leukemia virus transforming protein.

Authors:  O N Witte; A Ponticelli; A Gifford; D Baltimore; N Rosenberg; J Elder
Journal:  J Virol       Date:  1981-09       Impact factor: 5.103

3.  Viral src gene products are related to the catalytic chain of mammalian cAMP-dependent protein kinase.

Authors:  W C Barker; M O Dayhoff
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

4.  Expression of an Abelson murine leukemia virus-encoded protein in Escherichia coli causes extensive phosphorylation of tyrosine residues.

Authors:  J Y Wang; C Queen; D Baltimore
Journal:  J Biol Chem       Date:  1982-11-25       Impact factor: 5.157

5.  Transfection of fibroblasts by cloned Abelson murine leukemia virus DNA and recovery of transmissible virus by recombination with helper virus.

Authors:  S P Goff; C J Tabin; J Y Wang; R Weinberg; D Baltimore
Journal:  J Virol       Date:  1982-01       Impact factor: 5.103

6.  Isolation and biochemical characterization of partially transformation-defective mutants of avian myelocytomatosis virus strain MC29: localization of the mutation to the myc domain of the 110,000-dalton gag-myc polyprotein.

Authors:  G M Ramsay; M J Hayman
Journal:  J Virol       Date:  1982-03       Impact factor: 5.103

7.  Genome structure of Abelson murine leukemia virus variants: proviruses in fibroblasts and lymphoid cells.

Authors:  S P Goff; O N Witte; E Gilboa; N Rosenberg; D Baltimore
Journal:  J Virol       Date:  1981-05       Impact factor: 5.103

8.  Recovery of avian sarcoma virus from tumors induced by transformation-defective mutants.

Authors:  H Hanafusa; C C Halpern; D L Buchhagen; S Kawai
Journal:  J Exp Med       Date:  1977-12-01       Impact factor: 14.307

9.  A quantitative assay for transformation of bone marrow cells by Abelson murine leukemia virus.

Authors:  N Rosenberg; D Baltimore
Journal:  J Exp Med       Date:  1976-06-01       Impact factor: 14.307

View more
  8 in total

1.  Carboxyl-terminal determinants of Abelson protein important for lymphoma induction.

Authors:  K Parmar; R C Huebner; N Rosenberg
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

2.  The carboxyl terminus of v-Abl protein can augment SH2 domain function.

Authors:  D Warren; A J Heilpern; K Berg; N Rosenberg
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

3.  p53 deficiency increases transformation by v-Abl and rescues the ability of a C-terminally truncated v-Abl mutant to induce pre-B lymphoma in vivo.

Authors:  X Zou; F Cong; M Coutts; G Cattoretti; S P Goff; K Calame
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

4.  Decreased virus population diversity in p53-null mice infected with weakly oncogenic Abelson virus.

Authors:  Erica Marchlik; Richard Kalman; Naomi Rosenberg
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

5.  Recombinants within the tyrosine kinase region of v-abl and v-src identify a v-abl segment that confers lymphoid specificity.

Authors:  B Mathey-Prevot; D Baltimore
Journal:  Mol Cell Biol       Date:  1988-01       Impact factor: 4.272

6.  Temperature-sensitive mutants of Abelson murine leukemia virus deficient in protein tyrosine kinase activity.

Authors:  A Engelman; N Rosenberg
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

7.  Ras complements the carboxyl terminus of v-Abl protein in lymphoid transformation.

Authors:  K Parmar; N Rosenberg
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

8.  Direct interaction of Jak1 and v-Abl is required for v-Abl-induced activation of STATs and proliferation.

Authors:  N N Danial; J A Losman; T Lu; N Yip; K Krishnan; J Krolewski; S P Goff; J Y Wang; P B Rothman
Journal:  Mol Cell Biol       Date:  1998-11       Impact factor: 4.272

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.